Conclusions: These results demonstrated that downregulation of SPARC could decrease cell migration and invasion involving EMT via the p-FAK/p-ERK pathway that might serve as a novel therapeutic target against ESCC. The gene discussed is PTK2; the disease is esophageal squamous cell carcinoma.